Latest Biotech News

CMS launched a voluntary payment model intended to expand Medicare coverage of GLP‑1 weight‑loss drugs for eligible beneficiaries. The administration designed the pilot to test payment approaches...

The FDA approved Yartemlea, Omeros’s complement‑system drug, for a severe and potentially fatal complication of hematopoietic stem cell transplants, marking the first regulator‑confirmed therapy...

Johnson & Johnson terminated development of its experimental eczema candidate JNJ‑5939 (NM26) after a Phase 2 trial did not meet efficacy thresholds, ending hopes tied to the $1.25 billion...

Researchers published a framework for engineering adeno‑associated virus (AAV) vectors that dynamically respond to features of the tumor microenvironment to enhance tumor targeting and...

Researchers reported progress on nanovaccine platforms tailored to hepatocellular carcinoma (HCC), demonstrating nanoparticle‑mediated antigen presentation and immune activation in preclinical...

SpatialBench, a new benchmark suite, evaluates computational agents on 146 verifiable spatial biology problems drawn from real analysis workflows across five platforms (Vizgen MERFISH, 10x Visium,...

Recent advances summarize mechanisms behind CAR‑T cell therapy neurotoxicity, consolidating clinical signals, imaging correlates, and biomarker profiles to refine risk stratification and...

Researchers reported therapeutic approaches aimed at reversing multidrug resistance (MDR) in lung cancer, including novel small molecules, combination regimens, and delivery systems that restore...

A research team demonstrated that encapsulating cisplatin with silibinin inside biodegradable PLGA polymeric nanoparticles improves antitumor efficacy in cervical cancer models compared with free...

A comprehensive review examined the biomedical promise and broader effects of targeted protein degradation (TPD), surveying therapeutic potential, off‑target risks, and ecological considerations....

CMS launched a voluntary payment model designed to expand Medicare coverage for GLP‑1 weight‑loss drugs. The agency invited plans and providers to participate in a pilot that alters payment and...

The FDA approved Omeros’s complement inhibitor Yartemlea to treat a severe, often fatal complication of hematopoietic stem cell transplants. This marks the first approved therapy for the condition...

Johnson & Johnson said an experimental eczema medicine acquired for $1.25 billion failed to meet the company’s efficacy standards and the program will be discontinued. The decision closes a...

Biohaven reported that its potassium‑channel targeted candidate failed a Phase 2 trial in major depressive disorder, marking a second mid‑stage setback for the program. The company said the drug...

Researchers presented an intelligent AAV design framework that programs adeno‑associated viruses to respond to tumor microenvironment cues and activate selectively within malignancies. The...

A team unveiled nanovaccine platforms designed to elicit immune responses against hepatocellular carcinoma (HCC). The nanoparticle formulations target tumor antigens and deliver immune‑stimulatory...

SpatialBench was released as a suite of 146 verifiable spatial‑biology problems drawn from real workflows to evaluate agentic tools in biology. The benchmark spans five platforms (MERFISH, Seeker,...

A landmark study traced exosomal signatures that orchestrate lung‑tropic metastasis, identifying molecular cargo and microenvironment changes that favor colonization. The research used multiomics...

A new review and data synthesis examined the biological reach of targeted protein degradation (TPD) technologies, highlighting therapeutic promise and potential off‑target impacts across organs...

Researchers reported multiple preclinical strategies that overcome lung‑cancer drug resistance, including novel combinations that target epigenetic regulators and metabolic adaptations. Studies...